Document is current

Any future updates will be listed below

Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study

Crossref DOI link: https://doi.org/10.1038/s41392-024-01861-w

Published Online: 2024-06-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark